TY - JOUR
T1 - Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms
T2 - Mayo Clinic Study of Aging
AU - Krell-Roesch, Janina
AU - Rakusa, Martin
AU - Syrjanen, Jeremy A.
AU - van Harten, Argonde C.
AU - Lowe, Val J.
AU - Jack, Clifford R.
AU - Kremers, Walter K.
AU - Knopman, David S.
AU - Stokin, Gorazd B.
AU - Petersen, Ronald C.
AU - Vassilaki, Maria
AU - Geda, Yonas E.
N1 - Publisher Copyright: © 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association
PY - 2022
Y1 - 2022
N2 - Introduction: We examined the association between cerebrospinal fluid (CSF)-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms (NPS) in older non-demented adults. Methods: We included 784 persons (699 cognitively unimpaired, 85 with mild cognitive impairment) aged ≥ 50 years who underwent CSF amyloid beta (Aβ42), hyperphosphorylated tau 181 (p-tau), and total tau (t-tau) as well as NPS assessment using Beck Depression and Anxiety Inventories (BDI-II, BAI), and Neuropsychiatric Inventory Questionnaire (NPI-Q). Results: Lower CSF Aβ42, and higher t-tau/Aβ42 and p-tau/Aβ42 ratios were associated with BDI-II and BAI total scores, clinical depression (BDI-II ≥ 13), and clinical anxiety (BAI ≥ 10), as well as NPI-Q–assessed anxiety, apathy, and nighttime behavior. Discussion: CSF Aβ42, t-tau/Aβ42, and p-tau/Aβ42 ratios were associated with NPS in community-dwelling individuals free of dementia. If confirmed by a longitudinal cohort study, the findings have clinical relevance of taking into account the NPS status of individuals with abnormal CSF biomarkers.
AB - Introduction: We examined the association between cerebrospinal fluid (CSF)-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms (NPS) in older non-demented adults. Methods: We included 784 persons (699 cognitively unimpaired, 85 with mild cognitive impairment) aged ≥ 50 years who underwent CSF amyloid beta (Aβ42), hyperphosphorylated tau 181 (p-tau), and total tau (t-tau) as well as NPS assessment using Beck Depression and Anxiety Inventories (BDI-II, BAI), and Neuropsychiatric Inventory Questionnaire (NPI-Q). Results: Lower CSF Aβ42, and higher t-tau/Aβ42 and p-tau/Aβ42 ratios were associated with BDI-II and BAI total scores, clinical depression (BDI-II ≥ 13), and clinical anxiety (BAI ≥ 10), as well as NPI-Q–assessed anxiety, apathy, and nighttime behavior. Discussion: CSF Aβ42, t-tau/Aβ42, and p-tau/Aβ42 ratios were associated with NPS in community-dwelling individuals free of dementia. If confirmed by a longitudinal cohort study, the findings have clinical relevance of taking into account the NPS status of individuals with abnormal CSF biomarkers.
KW - Alzheimer's disease
KW - CSF amyloid beta 42
KW - CSF phosphorylated tau
KW - CSF total tau
KW - cerebrospinal fluid biomarkers
KW - neuropsychiatric symptoms
KW - non-demented
UR - http://www.scopus.com/inward/record.url?scp=85124563417&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/alz.12557
DO - https://doi.org/10.1002/alz.12557
M3 - Article
C2 - 35142047
SN - 1552-5260
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
ER -